Announcement PDF Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia +61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 1 ASX Announcement Racura Oncology Piggyback Options Expire Friday 29 May 2026 21 May 2026 Racura Oncology Limited (“Racura”) wishes to provide a final reminder to holders of the RACOPT43 options (Piggyback Options) that the options will expire at 5:00pm (AEST) on Friday, 29 May 2026. Each Piggyback Option entitles the holder to subscribe for one (1) share in Racura at $1.25. This is significantly lower than the current market price. Racura Oncology CEO and Managing Director, Dr Daniel Tillett said: “We have been advised that some optionholders have experienced random delays in the processing of their payments, with their bank holding their payments for several days for review. To avoid any risk of payments not clearing before the expiry date, holders who intend to exercise are encouraged to do so as early as possible.” The Options Prospectus dated 22 November 2023 contains information about the Piggyback Option Offers. Optionholders should read the Prospectus before exercising their options. Any Piggyback Options not exercised by the expiry date will lapse. For further details on how to exercise the options, holders should refer to the FAQ section at the end of this announcement. The Racura team once again thanks all shareholders for their ongoing support. -ENDS- Frequently Asked Questions How do I exercise my Piggyback Options? You can access your personalised Notice of Exercise of Options (Form) via Automic by taking one of the following steps: I already have an online account with the Automic Share registry • Please visit https://portal.automic.com.au/investor/home • Select: “Existing Users Sign In”. Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia +61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 2 • Once you have successfully signed in, click on “Documents and Statements”. • Download the RACOPT43 Option Exercise Form. • Submit your payment using the payment details provided on your Form. I don’t have an online account with Automic – but wish to register for one • Please visit https://singleholding.automic.com.au/signup • Select: “Racura Oncology Limited” from the dropdown list in the ISSUER field. • Enter your holder number HIN or SRN (from your latest Holding Statement). • Enter your Postcode (Aust only) or Country of Residence (if not Australia). • Tick box “I am not a robot”, then Next and Complete prompts. • Once you have successfully signed in, click on “Documents and Statements”. • Download the RACOPT43 Option Exercise Form. • Submit your payment using the payment details provided on Form. I don’t have an online account with Automic – but want to use Automic for the Offers only • Please visit https://singleholding.automic.com.au/login • Select: Racura Oncology Limited” from the dropdown list in the ISSUER field. • Enter your holder number HIN or SRN (from your latest Holding Statement). Enter your Postcode (Aust only) or Country of Residence (if not Australia). Tick box “I am not a robot”, then Access. • Once you have successfully signed in, click on “Documents and Statements”. • Download the RACOPT43 Option Exercise Form. • Submit your payment using the payment details provided on Form. Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia +61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 3 How do I find my SRN? Your Securityholder Reference Number (SRN) is listed on the holding statement sent to your registered address, as shown below, circled in red – all SRNs starts with the letter “I” followed by an 11-digit number. If you cannot locate, or did not receive a holding statement, please contact Automic by phone on 1300 288 664 (Australia) or +61 2 9698 5414 (overseas) or by emailing hello@automicgroup.com.au to request a new statement. Your SRN is listed on your holding statement. Note: SRN’s start with a capital letter “I” followed by an 11-digit number. Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia +61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 4 How do I add my SRN to my Automic account? Please follow the instructions on how to register or log in to your existing Automic account. Once logged into your Automic account, select “Add holding” (shown circled in the image below). Click on the “proceed to add holding” button. This will bring up the “Add Holding” form. Enter “Racura” as the Issuer and then enter your SRN in the SRN/HIN box, check the “I’m not a robot” box, and then press the “submit request” button. Your SRN holding will become visible in your Automic account after Automic processes the request which typically takes less than a day. Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia +61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 5 How do I find out how many Piggyback Options I have? You can see your options in your Automic account if you have added your SRN (see previous answer). Your Piggyback Options are listed under their code RACOPT43. You will only have Piggyback Options if you participated in the previous Bonus Option issued in 2023. What happens once I’ve exercised my Piggyback Options? Upon exercise the Piggyback Options, holders will be issued Ordinary Shares. The Ordinary Shares will be issued to the same SRN that previously held the Piggyback Options. You will be able to see your Ordinary Shares online once issued if you log into your Automic account and have added your SRN. What do I do if I did not receive my Options paperwork in the mail (or via email) from Automic? Holding Statements are mailed to the registered address (or emailed) according to the records held by Automic. If you did not receive this or can’t locate your paperwork, please contact Automic by phone on 1300 288 664 (Australia), or +61 2 9698 5414 (overseas) or by emailing hello@automicgroup.com.au. Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia +61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 6 How do I find the Options form in the Automic website Log into your Automic account once you have added your SRN. Click on the “Documents & Statements” menu on the left-hand side of the page. This will bring up the following page. If you can’t see the RACOPT43 Option Exercise Form on the first page, select “Other documents” from the CATERGORY menu and enter “Options” in the KEYWORDS box, and press the green “Search” button. You can then download the form with all the detail on how to pay, by clicking on the download icon. Further Information If you have any questions regarding your options or the exercise process, please contact Automic on 1300 288 664 (within Australia), +61 2 9698 5414 (from overseas) between 8:30am to 7:00pm (AEST) or by emailing corporate.actions@automicgroup.com.au. For other questions, you should consult your stockbroker, solicitor, accountant or other suitably qualified professional adviser. Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia +61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 7 About Racura Oncology Racura Oncology (ASX: RAC) is a Phase 3 clinical-stage biopharmaceutical company with a mission to silence cancer. Racura’s lead asset, (E,E)-bisantrene, is a small molecule anticancer agent that primarily functions via G4- DNA & RNA binding, leading to potent silencing of the important cancer growth regulator MYC. (E,E)- bisantrene has demonstrated therapeutic activity in cancer patients with a well-characterised safety profile. Recent discoveries made by Racura have enabled composition of matter IP filings that provides for 20 years of patent protection over (E,E)-bisantrene. Racura is advancing a proprietary formulation of (E,E)-bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a Phase 3 clinical program in acute myeloid leukaemia (AML), a Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin, where we aim to deliver both cardioprotection and enhanced anticancer activity for solid tumour patients. Racura has collaborated with Astex, Emory University, Purdue University, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong, and University of Newcastle. Racura is actively exploring partnerships, licence agreements, or a commercial merger and acquisition to accelerate access to RC220 for patients with cancer across the world. Learn more at www.racuraoncology.com. If you have any questions on this announcement, or any past Racura announcements, please visit our Interactive Announcements page. Racura encourages all investors to go paperless by registering their details with the Company’s share registry, Automic Registry Services, at www.automicgroup.com.au. Release authorised by Media Contact Daniel Tillett, CEO Cherie Hartley +61 418 737 020 info@racuraoncology.com cherie.hartley@irdepartment.com.au